Thierry Chauche
Directeur Financier/CFO chez SAGIMET BIOSCIENCES INC.
Profil
Mr. Thierry Chauche is a Chief Financial & Accounting Officer at Sagimet Biosciences, Inc. Mr. Chauche was previously employed as a Chief Financial Officer by Provention Bio, Inc. and a VP, Head-Strategic Financial Planning & Analysis by Alexion Pharmaceuticals, Inc. He received his graduate degree from école Des Ponts Paristec and an MBA from The Wharton School of the University of Pennsylvania.
Postes actifs de Thierry Chauche
| Sociétés | Poste | Début |
|---|---|---|
| SAGIMET BIOSCIENCES INC. | Directeur Financier/CFO | 06/05/2024 |
Anciens postes connus de Thierry Chauche
| Sociétés | Poste | Fin |
|---|---|---|
| PROVENTION BIO, INC. | Directeur Financier/CFO | 01/04/2023 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2021 |
Formation de Thierry Chauche
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| école Des Ponts Paristec | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SAGIMET BIOSCIENCES INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |